CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25TH Annual ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Northera (droxidopa) development program.
Mr. Oliveto's presentation will be webcast live and archived for 30 days on Chelsea's website, www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure.www.chelseatherapeutics.com
Fara Berkowitz/Susan Kim